CSIMarket
 
Outlook Therapeutics Inc   (OTLK)
Other Ticker:  
 
 
Price: $8.2400 $2.51 43.805%
Day's High: $10.7199 Week Perf: 5.4 %
Day's Low: $ 5.62 30 Day Perf: -1.97 %
Volume (M): 2,274 52 Wk High: $ 40.60
Volume (M$): $ 18,734 52 Wk Avg: $16.97
Open: $5.64 52 Wk Low: $4.00



 Market Capitalization (Millions $) 2,145
 Shares Outstanding (Millions) 260
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -52
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 0

Outlook Therapeutics Inc
Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative ophthalmic products. The company is specifically dedicated to creating therapies for diseases and conditions that affect the retina and optic nerve. Outlook Therapeutics works on advanced biologic products that can improve the lives of patients with vision disorders. They prioritize developing solutions that are safe, effective, and affordable.


   Company Address: 485 Route 1 South Iselin 8830 NJ
   Company Phone Number: 619-3990   Stock Exchange / Ticker: NASDAQ OTLK
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Financing Agreement

Outlook Therapeutics Closes Private Placement, Raising Up to $159 Million for Ophthalmic Bevacizumab Treatment

Published Mon, Mar 18 2024 9:10 PM UTC



Iselin-based biopharmaceutical company, Outlook Therapeutics, has successfully concluded its private placement, securing upfront gross proceeds of approximately $60 million. In addition, the company has the potential to further bolster its financial position with up to $99 million upon the exercise of warrants issued in the private placement. This funding will supp...

Outlook Therapeutics Inc

Operating Deficit Improves to $-15.7 Million in Q1 2024 Earnings Season for Biotech & Pharma Firm

Outlook Therapeutics Inc, a biopharmaceutical company based in Iselin, New Jersey, recently reported its financial results for the first quarter of fiscal year 2024. The company revealed an operating deficit of $-10.323122 million for the quarter, showcasing a decrease from the prior year's deficit.
Despite the operating deficit, the company has been making significant progress in its pursuit of FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases. The NORSE EIGHT clinical trial, evaluating the efficacy of their drug candidate, ONS-5010, in neovascular age-related macular degeneration (wet AMD) patients, has successfully dosed its first subject. This milestone marks a positive step forward in the company's mission to provide more effective and accessible therapies for patients suffering from retinal diseases.

Clinical Study

A Promising Step Forward: Outlook Therapeutics' ONS-5010 Shows Early Progress in NEJM Published Clinical Trial

Published Wed, Jan 31 2024 1:05 PM UTC

Outlook Therapeutics, a renowned biopharmaceutical company, marked a significant milestone in its pursuit of FDA approval for the first ophthalmic formulation of bevacizumab in the treatment of retinal diseases. The company proudly announced that the NORSE EIGHT clinical trial, evaluating the efficacy of their innovative drug candidate, ONS-5010, in neovascular age-related m...

Clinical Study

Outlook Therapeutics Secures FDA Agreement for NEORE EIGHT Trial and Raises $172 Million to Advance ONS-5010 in Treatment of Neovascular Age-Related Macular Degeneration

Published Tue, Jan 23 2024 1:00 PM UTC

Outlook Therapeutics, a biopharmaceutical company, has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the NORSE EIGHT clinical trial protocol. This trial will evaluate ONS-5010, the first ophthalmic formulation of bevacizumab, in neovascular age-related macular degeneration (AMD) subjects. Additionally, the company has secured a private...

Outlook Therapeutics Inc

Outlook Therapeutics Inc Reveals Significant Operating Losses in Fourth Quarter of 2023



Outlook Therapeutics, a biopharmaceutical company focused on obtaining FDA approval for the first ophthalmic formulation of bevacizumab, recently announced its financial results for the fiscal year ending September 30, 2023. Notably, the company showcased advancements and positive developments in its pursuit of regulatory approval. This article will discuss the financial results and their potential impact on Outlook Therapeutics' future prospects.
Financial Performance:
Despite operating losses, Outlook Therapeutics demonstrated marked improvement compared to the previous fiscal year. For the fourth quarter of 2023, the company's operating loss narrowed to $12.459019 million from $13.987532 million in the same period of 2022. Additionally, the company saw diminishing returns decline to $12.991 million from $14.345 million in Q4 2022. These figures indicate a positive trend, showcasing the company's efforts to become a successful player in the industry.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com